SummaryParticipants must have document IDH1 R132C, R132L, R132G, R132H, or R132S gene-mutated disease. All eligible participants will receive a targeted therapy drug called Ivosidenib (500mg), which is to be taken orally as two 250mg tablets once daily for an unlimited amount of continuous 28-day cycles.
Treatment TypeSystemic therapy (chemotherapy, hormone therapy or immunotherapy)
Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma